Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sera Prognostics ( (SERA) ) has provided an announcement.
On January 6, 2025, a study abstract published by the Society for Maternal Fetal Medicine highlighted the results of the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal Outcomes (PRIME) study. These findings will be further detailed at the SMFM 2025 Pregnancy Meeting and discussed by Sera Prognostics through a conference call on February 6, 2025, indicating the company’s engagement in advancing maternal and fetal health research.
More about Sera Prognostics
YTD Price Performance: -7.56%
Average Trading Volume: 92,941
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $260M
For a thorough assessment of SERA stock, go to TipRanks’ Stock Analysis page.